. . "L\u2019entreprise pharmaceutique berlinoise Jerini AG est sp\u00E9cialis\u00E9e dans la recherche, le d\u00E9veloppement et la commercialisation de m\u00E9dicaments innovants, de nature peptidique. Sa plate-forme technologique \u00AB Peptides-to-Drugs \u00BB (P2D) lui permet de d\u00E9velopper des m\u00E9dicaments pour des maladies pour lesquelles il n\u2019existait jusqu\u2019\u00E0 pr\u00E9sent aucune possibilit\u00E9 de traitement, ou seulement des possibilit\u00E9s de traitement r\u00E9duites. En plus du d\u00E9veloppement de ses propres substances actives, l\u2019entreprise collabore avec d\u2019autres soci\u00E9t\u00E9s. L\u2019entreprise pr\u00E9voit de commercialiser elle-m\u00EAme ses m\u00E9dicaments pour des indications de niche, et dans les domaines d\u2019indication plus vastes, d\u2019assurer la commercialisation en coop\u00E9ration avec des partenaires."@fr . . . "Berlin, Germany"@en . . . "Die Jerini AG war ein Pharmaunternehmen, das auf peptidbasierte Arzneimittel spezialisiert war. Mithilfe einer Technologieplattform \u201EPeptides-to-Drugs\u201C (P2D) wurde an Wirkstoffen f\u00FCr Medikamente in den Indikationsbereichen Augenheilkunde, Onkologie und Entz\u00FCndungserkrankungen geforscht. Neben der Entwicklung eigener Wirkstoffe unterhielt das Unternehmen Kooperationen mit anderen Unternehmen. 2008 wurde Jerini vom britischen Unternehmen Shire plc \u00FCbernommen."@de . . . . . . . "139"^^ . . "1994"^^ . . . . . "139"^^ . . . . . . . . "Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008."@en . "Jerini company logo"@en . "L\u2019entreprise pharmaceutique berlinoise Jerini AG est sp\u00E9cialis\u00E9e dans la recherche, le d\u00E9veloppement et la commercialisation de m\u00E9dicaments innovants, de nature peptidique. Sa plate-forme technologique \u00AB Peptides-to-Drugs \u00BB (P2D) lui permet de d\u00E9velopper des m\u00E9dicaments pour des maladies pour lesquelles il n\u2019existait jusqu\u2019\u00E0 pr\u00E9sent aucune possibilit\u00E9 de traitement, ou seulement des possibilit\u00E9s de traitement r\u00E9duites. En plus du d\u00E9veloppement de ses propres substances actives, l\u2019entreprise collabore avec d\u2019autres soci\u00E9t\u00E9s. L\u2019entreprise pr\u00E9voit de commercialiser elle-m\u00EAme ses m\u00E9dicaments pour des indications de niche, et dans les domaines d\u2019indication plus vastes, d\u2019assurer la commercialisation en coop\u00E9ration avec des partenaires."@fr . . . . "Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008. Jerini started operations in 1994. Jerini's subsidiaries Jerini US Inc. and JPT Peptide Technologies GmbH, provider of peptides and peptide microarrays, were acquired by Theracode GmbH, Mainz in 2009. Jerini was financed with venture capital provided by TVM and HealthCap. It went public on the Prime Standard of the Frankfurt Stock Exchange (JI4), and had raised a total of over 130 million Euro in public and private financing to date."@en . . "Jerini AG \u00E8 un'azienda farmaceutica con sede a Berlino la cui attivit\u00E0 principale \u00E8 basata sulla scoperta, lo sviluppo e la commercializzazione di nuovi farmaci peptidici. La societ\u00E0 opera nel settore delle malattie rare per le quali non esistono trattamenti o per le quali le opzioni terapeutiche sono limitate, settore nel quale ha sviluppato in proprio e in collaborazione con partner una pipeline di prodotti. Firazyr, il principale farmaco della societ\u00E0, \u00E8 stato sviluppato per il trattamento dell'angioedema ereditario e sar\u00E0 commercializzato in Europa a partire dal terzo trimestre 2008. Jerini ha inoltre dato avvio ad altri programmi di sviluppo in diverse aree terapeutiche ed in particolare in oftalmologia, oncologia e nel campo delle infiammazioni. Il 3 luglio 2008 Jerini e Shire Limite"@it . . . . . . "Jerini AG \u00E8 un'azienda farmaceutica con sede a Berlino la cui attivit\u00E0 principale \u00E8 basata sulla scoperta, lo sviluppo e la commercializzazione di nuovi farmaci peptidici. La societ\u00E0 opera nel settore delle malattie rare per le quali non esistono trattamenti o per le quali le opzioni terapeutiche sono limitate, settore nel quale ha sviluppato in proprio e in collaborazione con partner una pipeline di prodotti. Firazyr, il principale farmaco della societ\u00E0, \u00E8 stato sviluppato per il trattamento dell'angioedema ereditario e sar\u00E0 commercializzato in Europa a partire dal terzo trimestre 2008. Jerini ha inoltre dato avvio ad altri programmi di sviluppo in diverse aree terapeutiche ed in particolare in oftalmologia, oncologia e nel campo delle infiammazioni. Il 3 luglio 2008 Jerini e Shire Limited hanno annunciato una partnership strategica che prevede l'acquisizione di Jerini da parte di Shire al prezzo di Euro 6,25 per azione. Il management prevede che l'acquisizione sar\u00E0 completata entro l'autunno 2008."@it . . . . . . . . . "Jerini"@de . . . . . "1112864986"^^ . . . . . . . . . . . "Jerini"@it . . . . "Jerini AG"@en . "6588551"^^ . "jerini 285 93.jpg"@en . . . . . . . . . . . . "6497"^^ . . "Die Jerini AG war ein Pharmaunternehmen, das auf peptidbasierte Arzneimittel spezialisiert war. Mithilfe einer Technologieplattform \u201EPeptides-to-Drugs\u201C (P2D) wurde an Wirkstoffen f\u00FCr Medikamente in den Indikationsbereichen Augenheilkunde, Onkologie und Entz\u00FCndungserkrankungen geforscht. Neben der Entwicklung eigener Wirkstoffe unterhielt das Unternehmen Kooperationen mit anderen Unternehmen. 2008 wurde Jerini vom britischen Unternehmen Shire plc \u00FCbernommen."@de . "Jerini"@en . "Berlin, Germany"@en . . . "Jerini"@fr . . . . "Jerini AG"@en . . . . . .